StocksFundsScreenerSectorsWatchlists
IOVA

IOVA - Iovance Biotherapeutics Inc Stock Price, Fair Value and News

14.82USD+0.72 (+5.11%)Delayed as of 28 Mar 2024, 01:04 pm ET

Market Summary

IOVA
USD14.82+0.72
Delayedas of 28 Mar 2024, 01:04 pm
5.11%

IOVA Alerts

  • 3 major insider buys recently.

IOVA Stock Price

View Fullscreen

IOVA RSI Chart

IOVA Valuation

Market Cap

3.9B

Price/Earnings (Trailing)

-8.87

Price/Sales (Trailing)

3.3K

EV/EBITDA

-8.81

Price/Free Cashflow

-10.25

IOVA Price/Sales (Trailing)

IOVA Profitability

Operating Margin

-804.54%

EBT Margin

-37465.52%

Return on Equity

-75.95%

Return on Assets

-56.9%

Free Cashflow Yield

-9.75%

IOVA Fundamentals

IOVA Revenue

Revenue (TTM)

1.2M

IOVA Earnings

Earnings (TTM)

-444.0M

Earnings Growth (Yr)

-10.5%

Earnings Growth (Qtr)

-2.3%

Breaking Down IOVA Revenue

52 Week Range

4.0115.17
(Low)(High)

Last 7 days

8.0%

Last 30 days

64.1%

Last 90 days

80.1%

Trailing 12 Months

124.0%

How does IOVA drawdown profile look like?

IOVA Financial Health

Current Ratio

2.79

IOVA Investor Care

Shares Dilution (1Y)

24.56%

Diluted EPS (TTM)

-1.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230001.2M

Tracking the Latest Insider Buys and Sells of Iovance Biotherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 04, 2024
bilinsky igor
sold (taxes)
-123,588
16.96
-7,287
chief operating officer
Mar 04, 2024
bilinsky igor
acquired
-
-
14,061
chief operating officer
Mar 04, 2024
graf finckenstein friedrich
acquired
-
-
15,623
chief medical officer
Mar 04, 2024
graf finckenstein friedrich
sold (taxes)
-136,579
16.96
-8,053
chief medical officer
Mar 04, 2024
vogt frederick g
sold (taxes)
-194,175
16.96
-11,449
interim ceo & general counsel
Mar 04, 2024
vogt frederick g
acquired
-
-
41,662
interim ceo & general counsel
Feb 20, 2024
dukes iain d.
bought
292,800
9.15
32,000
-
Feb 20, 2024
rothbaum wayne p.
bought
45,750,000
9.15
5,000,000
-
Feb 20, 2024
mcpeak merrill a
bought
2,287,500
9.15
250,000
-
Jan 16, 2024
bilinsky igor
sold (taxes)
-13,199
8.37
-1,577
chief operating officer

1–10 of 50

Which funds bought or sold IOVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
169
5,869
7,406
-%
Mar 11, 2024
VANGUARD GROUP INC
added
3.02
84,715,400
185,468,000
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
95.64
42,737,600
59,862,200
-%
Feb 29, 2024
Scarborough Advisors, LLC
new
-
49.00
49.00
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
406,062
926,901
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
added
0.14
42,961,300
97,392,600
2.17%
Feb 23, 2024
Chicago Partners Investment Group LLC
added
15.04
95,621
157,276
0.01%
Feb 20, 2024
VOISARD ASSET MANAGEMENT GROUP, INC.
new
-
2,220
2,220
-%
Feb 16, 2024
CIM INVESTMENT MANAGEMENT INC
unchanged
-
49,307
111,974
0.04%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-8.91
10,272,000
26,640,000
-%

1–10 of 43

Are Funds Buying or Selling IOVA?

Are funds buying IOVA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IOVA
No. of Funds

Unveiling Iovance Biotherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 19, 2024
quogue capital llc
11.6%
3e+07
SC 13D/A
Mar 01, 2024
perceptive advisors llc
6.9%
19,221,743
SC 13G
Feb 14, 2024
point72 asset management, l.p.
0%
0
SC 13G/A
Feb 14, 2024
perceptive advisors llc
4.7%
11,979,415
SC 13G/A
Feb 13, 2024
vanguard group inc
8.91%
22,812,820
SC 13G/A
Feb 09, 2024
mhr fund management llc
6.9%
17,605,902
SC 13G/A
Jan 26, 2024
blackrock inc.
7.5%
19,071,756
SC 13G/A
Jan 25, 2024
state street corp
6.42%
16,424,388
SC 13G/A
Oct 27, 2023
quogue capital llc
15.84%
2.5e+07
SC 13D/A
Feb 17, 2023
point72 asset management, l.p.
4.6%
7,347,600
SC 13G

Recent SEC filings of Iovance Biotherapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 19, 2024
SC 13D/A
13D - Major Acquisition
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 06, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Iovance Biotherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Iovance Biotherapeutics Inc News

Latest updates
InvestorsObserver • 34 minutes ago
Seeking Alpha • 25 Mar 2024 • 06:29 pm
Defense World • 24 Mar 2024 • 09:12 am
The Motley Fool • 02 Mar 2024 • 08:00 am
Barron's • 20 Feb 2024 • 08:00 am

Iovance Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q2
Revenue-100.0%-469,000238,000
Cost Of Revenue-100.0%-4,340,0002,050,000
Costs and Expenses2.4%121,738,000118,830,000110,324,000
  S&GA Expenses10.9%29,903,00026,964,00021,927,000
  R&D Expenses-0.1%87,470,00087,526,00086,347,000
EBITDA Margin-Infinity%-364--
Income Taxes-44.8%-1,800,000-1,243,000-477,000
Earnings Before Taxes-2.7%-118,138,000-115,003,000-107,005,000
EBT Margin-Infinity%-374--
Net Income-2.3%-116,379,000-113,760,000-106,528,000
Net Income Margin-Infinity%-373--
Free Cashflow0.1%-87,499,000-87,627,000-103,520,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-8.4%780852757825664546611701777829853751768782818288345396436462481
  Current Assets-19.5%308383275638479370432490508583667605636724783256316367411445475
    Cash Equivalents-57.1%11526823054323211810892.0078.0059.0083.0013273.0068.0016153.0019.0039.0077.0054.0082.00
  Inventory12.8%10.009.0010.00------------------
  Net PPE0.8%11411311311010510110110310188.0080.0073.0059.0039.0019.0014.009.006.004.004.003.00
Liabilities9.8%19617817915816415213814915613010810311270.0059.0045.0046.0041.0039.0027.0015.00
  Current Liabilities21.3%11091.0089.0087.0091.0079.0064.0077.0089.0065.0061.0055.0055.0064.0055.0040.0039.0035.0034.0022.0014.00
Shareholder's Equity-13.3%585674579667500394473552622698744647656712758243299355397435466
  Retained Earnings-6.1%-2,012-1,896-1,782-1,675-1,568-1,463-1,363-1,264-1,172-1,073-986-905-830-761-703-640-570-507-457-4100.00
  Additional Paid-In Capital0.6%2,5942,5792,3602,3432,0691,8591,8391,8181,7951,7711,7311,5531,4871,4731,4618838690.000.00845839
Shares Outstanding0.1%256256225224188158157157157152151149---------
Float---1,400---1,600---3,800---3,700---2,900--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations0.1%-83,970-84,050-93,985-99,815-77,671-63,649-77,635-73,802-53,849-57,693-54,008-62,391-62,692-40,515-36,635-65,292-53,822-42,182-33,795-29,090-31,549
  Share Based Compensation-9.0%14,39915,82116,74015,66519,50919,78022,46822,26519,10419,30614,41416,94110,23210,70610,5379,4125,4076,5986,4265,8465,254
Cashflow From Investing7.8%-72,845-79,014-156,779153,39646173,71595,76386,51669,33812,748-159,16577,21158,753-52,955-423,756100,10526,8143,49558,6831,033-206,382
Cashflow From Financing-99.5%962202,8001,025258,172190,575225-2,0671,4174,15020,772163,98250,3642,9581,166568,4653,8332,0886643,381-2.00239,345

IOVA Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Consolidated Statements of Operations   
Total revenue$ 1,189  
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]us-gaap:ProductMember  
Costs and expenses   
Cost of sales$ 10,755  
Research and development344,077$ 294,781$ 259,039
Selling, general and administrative106,916104,09783,664
Total costs and expenses461,748398,878342,703
Loss from operations(460,559)(398,878)(342,703)
Other income   
Interest income, net13,0432,985451
Net Loss before income taxes(447,516)(395,893)(342,252)
Income tax benefit3,47900
Net Loss$ (444,037)$ (395,893)$ (342,252)
Net Loss Per Share of Common Stock, Basic$ (1.89)$ (2.49)$ (2.23)
Net Loss Per Share of Common Stock, Diluted$ (1.89)$ (2.49)$ (2.23)
Weighted Average Shares of Common Stock Outstanding, Basic235,131159,259153,406
Weighted Average Shares of Common Stock Outstanding, Diluted235,131159,259153,406

IOVA Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 114,888$ 231,731
Trade accounts receivable151 
Short-term investments164,979240,114
Inventory10,372 
Prepaid expenses and other assets17,4587,271
Total Current Assets307,848479,116
Property and equipment, net114,030105,232
Intangible assets, net229,258 
Operating lease right-of-use assets62,51573,015
Restricted cash66,4306,430
Long-term assets270189
Total Assets780,351663,982
Current Liabilities  
Accounts payable33,12326,603
Accrued expenses69,40652,295
Operating lease liabilities7,77712,587
Total Current Liabilities110,30691,485
Non-Current Liabilities  
Operating lease liabilities - non-current67,08571,859
Deferred tax liabilities17,347 
Long-term note payable1,0001,000
Total Non-Current Liabilities85,43272,859
Total Liabilities195,738164,344
Commitments and contingencies
Stockholders' Equity  
Common stock, $0.000041666 par value; 500,000,000, and 300,000,000 shares authorized, 256,135,715 and 187,812,072 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively118
Accumulated other comprehensive income (loss)2,526(902)
Additional paid-in capital2,594,4482,068,867
Accumulated deficit(2,012,375)(1,568,338)
Total Stockholders' Equity584,613499,638
Total Liabilities and Stockholders' Equity780,351663,982
Series A Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value00
Series B Convertible Preferred Stock  
Stockholders' Equity  
Preferred stock, Value$ 3$ 3
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
 CEO
 WEBSITEwww.iovance.com
 EMPLOYEES503

Iovance Biotherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Iovance Biotherapeutics Inc? What does IOVA stand for in stocks?

IOVA is the stock ticker symbol of Iovance Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Iovance Biotherapeutics Inc (IOVA)?

As of Wed Mar 27 2024, market cap of Iovance Biotherapeutics Inc is 3.94 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IOVA stock?

You can check IOVA's fair value in chart for subscribers.

What is the fair value of IOVA stock?

You can check IOVA's fair value in chart for subscribers. The fair value of Iovance Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Iovance Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IOVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Iovance Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether IOVA is over valued or under valued. Whether Iovance Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Iovance Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOVA.

What is Iovance Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, IOVA's PE ratio (Price to Earnings) is -8.87 and Price to Sales (PS) ratio is 3.31 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Iovance Biotherapeutics Inc's stock?

In the past 10 years, Iovance Biotherapeutics Inc has provided 0.058 (multiply by 100 for percentage) rate of return.